Miraculins Inc. (MOM.V)
-TSXV 0.07 0.00(0.00%) May 17, 11:50AM EDT
| Prev Close: | 0.07 |
|---|
| Open: | 0.07 |
|---|
| Bid: | 0.07 |
|---|
| Ask: | 0.08 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.07 - 0.07 |
|---|
| 52wk Range: | 0.06 - 0.17 |
|---|
| Volume: | 143,000 |
|---|
| Avg Vol (3m): | 114,951 |
|---|
| Market Cap: | 4.62M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Miraculins Reports First Quarter Financial Results for Fiscal 2013Marketwired(Fri, Apr 26)
- Miraculins Reports First Quarter Financial Results for Fiscal 2013Marketwired(Fri, Apr 26)
- Miraculins Executes Term Sheet to Acquire the SCOUT DS(R) Non-Invasive Diabetes Screening TechnologyMarketwired(Mon, Apr 15)
- Miraculins Executes Term Sheet to Acquire the SCOUT DS(R) Non-Invasive Diabetes Screening TechnologyMarketwired(Mon, Apr 15)
- Miraculins Announces Closing of Private Placement OfferingMarketwired(Mon, Apr 8)
- Miraculins Announces Closing of Private Placement OfferingMarketwired(Mon, Apr 8)
- Miraculins Announces Private Placement OfferingMarketwired(Mon, Mar 25)
- Miraculins Announces Private Placement OfferingMarketwired(Mon, Mar 25)
- Miraculins Announces National Accreditation of Pharmacist Education Program on Cardiovascular Risk Assessment with Focus on Skin CholesterolMarketwired(Fri, Mar 15)
- Miraculins Announces National Accreditation of Pharmacist Education Program on Cardiovascular Risk Assessment with Focus on Skin CholesterolMarketwired(Fri, Mar 15)
- Miraculins to License Additional Preeclampsia Technology from Mount Sinai HospitalMarketwired(Mon, Mar 11)
- Miraculins to License Additional Preeclampsia Technology from Mount Sinai HospitalMarketwired(Mon, Mar 11)
- PreVu(R) Skin Cholesterol Clinics Rollout NationallyMarketwired(Wed, Feb 27)
- PreVu(R) Skin Cholesterol Clinics Rollout NationallyMarketwired(Wed, Feb 27)
- Miraculins Moves Closer to PreVu(R) Expansion in U.S. and UK/EU through Key Market Development Team AppointmentsMarketwired(Tue, Feb 19)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 28.29 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Miraculins Inc., a medical diagnostic company, focuses on acquiring, developing, and commercializing non-invasive tests for unmet clinical needs in Canada.
View More 
0.80%